Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
02 mars 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat...
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
28 févr. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
27 févr. 2018 16h05 HE
|
Melinta Therapeutics
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20 févr. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29 janv. 2018 07h00 HE
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
18 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Completes Acquisition of The Medicines Company’s Infectious Disease Portfolio
08 janv. 2018 07h00 HE
|
Melinta Therapeutics
— Expands portfolio to four marketed antibiotics, with peak sales potential over $1 billion —— Creates premier commercial stage global antibiotic franchise with the addition of Vabomere™(meropenem and...
Melinta Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Appoints Lisa DeFrancesco as Senior Vice President of Investor Relations
02 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat...
Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company
29 nov. 2017 07h00 HE
|
Melinta Therapeutics
- Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela®, Vabomere®, Orbactiv®, and Minocin IV® - - Peak sales potential of the...